Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Price History
|
Ratios
|
Insiders
Bullboard - Stock Discussion Forum
Apollomics Inc
APLM
Healthcare
Biotechnology
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell...
lung cancer and other solid tumors with MET dysregulation; APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways that is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its immuno-oncology product candidates comprise APL-501, APL-502, and APL-801. The company was founded in 2015 and is based in Foster City, California.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Bullboard (NDAQ:APLM)
New Post
View:
Posts & Comments
Threaded Posts
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 16, 2023 8:30am
New Press Release - Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer
Apollomics’ partner, Avistone Biotechnology, received approval from Chinese National Medical Products Administration (NMPA) to commercialize vebreltinib (APL-101) in China Compelling clinical data serving as basis of this approval supports continued development of vebreltinib for the rest of...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 31, 2023 8:30am
New Press Release - Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation
FOSTER CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced the addition of two new cohorts in its...
read article.
(657)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 27, 2023 10:57am
APLM.....don't get lured into this
JMHO
(657)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 27, 2023 10:38am
APLM....pardon me....All sidewats action to lure
the unsuspecting Rangebound trading....82 to 95 Trade accordingly with stops
(657)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 27, 2023 10:29am
APLM....and now the downward spiral til red
JMHO
(657)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 27, 2023 10:28am
APLM....Cha Ching
Ya gotta be fast
(657)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 27, 2023 10:24am
APLM ....now sell 92!!!!!
Cheers !
(657)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 27, 2023 10:22am
APLM .... Any gamblers out there ???
Possible 2 x's bottom at 82 If you are proned to play spear-catcher....do it now with a tight stop
(657)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 27, 2023 10:12am
APLM ....and now for the pièce de ré·sis·tance
The big ol Green to red move Wait for it
(657)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 27, 2023 10:04am
APLM.....just tapped sub 90 cents
sheesh
(657)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 27, 2023 9:57am
APLM....sub $1 now
What af'king game
(657)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 27, 2023 9:49am
APLM.....This is a reverse rocket
otherwise known as a Rock
(657)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 27, 2023 9:40am
APLM....1st Halt....on the way down
seldom a good thing....last at $1.21 This is done ; )
(657)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 27, 2023 9:36am
APLM....has to hold $1.29
or it's done like dinner
(657)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 27, 2023 9:30am
APLM...early a.m runner up on NR this a.m
Caveat emptor ; )
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
Featured News Links
Sorrento Resources Announces Drilling Contract and Receives Permit to Drill Bottom Brook Project
Podcasts